Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Giliad good results

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Jun 20, 2024 1:59pm

95 Views

Post# 36098402

RE:Giliad good results

Obviously might not help Trogarzo sales in the future. Anyway, it's expected in trhe end. The reality is that it will be probably many years before it affects Thera. Maybe never will.

<< Previous

Bullboard Posts

Next >>

New Pacific Metals delivers robust Silver Sand pre-feasibility study